Background & relevance

Standard first-line treatment for mUCa patients has been platinum-based chemotherapy for many years. The advent of immunotherapy, antibody-drug conjugates and FGFR inhibitors broadens the treatment landscape and paves the way for more personalised medicine.

Regulatory approval status of drugs for mUCa (status 1 July 2022)

CPS: combined positive score